19:30 , Jul 13, 2018 |  BC Week In Review  |  Clinical News

HPV testing improves cervical intraepithelial neoplasia detection vs. liquid-based cytology

The Canadian Institutes of Health Research (CIHR) published data from a study in the...
07:00 , May 10, 2010 |  BC Week In Review  |  Clinical News

Hybrid Capture 2 High-Risk HPV DNA Test: Data

Five-year follow-up data from the British HART study in 8,735 women showed that women who were HPV negative at baseline as determined by the Digene HPV test had a lower rate of developing cervical intraepithelial...
08:00 , Jan 25, 2010 |  BC Week In Review  |  Clinical News

Digene HPV test diagnostic data

Researchers at the Center for Cancer Prevention in Turin and colleagues reported data from an Italian study in 94,370 women in which there was a significantly lower number of cases of invasive cervical cancer after...
08:00 , Nov 23, 2009 |  BC Week In Review  |  Clinical News

Hybrid Capture 2 High-Risk HPV DNA Test: Data

Data from a Finnish study in 108,425 women undergoing routine cervical cancer screening showed the Hybrid Capture 2 High-Risk HPV DNA Test with Pap smear test detected 44%, 39% and 22% more cases of cervical...
07:00 , Jun 29, 2009 |  BC Week In Review  |  Clinical News

Digene HPV DNA test: Phase IV data

Data from the U.K. ARTISTIC trial in 24,510 women showed that Digene HPV Test plus liquid-based cytology (LBC) met the primary endpoint of producing a significantly lower detection rate of cervical intraepithelial neoplasia grade 3...
07:00 , Apr 13, 2009 |  BC Week In Review  |  Clinical News

Digene HPV Test data

Data from a 4-arm Indian trial in 131,746 healthy women ages 30-59 showed that the incidence of stage II or higher cervical cancer was 53% lower in subjects undergoing HPV testing with Qiagen's Digene HPV...
07:00 , Jun 12, 2006 |  BC Week In Review  |  Clinical News

Digene HPV Test diagnostic data

Data from 33,364 women enrolled in the Italian NTCC study showed that the Hybrid Capture 2 High-Risk HPV DNA Test was a more sensitive tool for cervical cancer screening than either conventional or liquid-based cytology...
08:00 , Jan 26, 2004 |  BC Week In Review  |  Clinical News

hc2 High-Risk human papillomavirus regulatory update

France approved reimbursement of DIGE's HPV diagnostic for follow-up evaluation of women with borderline Pap test results. The agency also said it would study use of the test for routine, primary screening for cervical cancer...
08:00 , Jan 5, 2004 |  BioCentury  |  Finance

4Q approvals

4Q approvals...
08:00 , Dec 8, 2003 |  BC Week In Review  |  Clinical News

hc2 High-Risk human papillomavirus regulatory update

DIGE received European CE Mark approval for its patient screening tests. The CE Mark means the tests comply with European regulatory requirements and allows DIGE to continue selling the HPV, chlamydia and gonorrhea tests across...